永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 02-24 15:51:41

2.640

+0.040

+1.54%

最高2.670	最低2.610	成交量6.70万
今开2.670	昨收2.600	日振幅2.31%
总市值16.32亿	流通市值16.32亿	总股本6.18亿
成交额17.73万	换手率0.01%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.64,"timestamp":1771919501608,"preClose":2.6,"halted":0,"volume":67020,"delay":0,"changeRate":0.015384615384615398,"floatShares":618000000,"shares":618000000,"eps":-0.363229,"marketStatus":"已收盘","change":0.04,"latestTime":"02-24 15:51:41","open":2.67,"high":2.67,"low":2.61,"amount":177260,"amplitude":0.023077,"askPrice":2.64,"askSize":9000,"bidPrice":2.61,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.397,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.6,"openAndCloseTimeList":[[1771896600000,1771905600000],[1771909200000,1771920000000]],"volumeRatio":0.382154,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2613871794","title":"康哲药业(00867)：创新药磷酸芦可替尼乳膏增加特应性皮炎(AD)适应症中国上市许可申请获受理并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871794","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613871794?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:49","pubTimestamp":1771926559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年2月24日获得中国国家药品监督管理局受理磷酸芦可替尼乳膏轻中度特应性皮炎的新药上市许可申请。且该项NDA因“符合儿童生理特征的儿童用药品新品种、剂型和规格”，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1574","LU2488822045.USD","IE00BVYPNP33.GBP","BK1161","IE00BMCWC346.EUR","SG9999015986.USD","SG9999015978.USD","IE00BGHQDM52.EUR","BK1191","IE00BVYPNQ40.USD","BK1593","SG9999015952.SGD","SG9999004220.SGD","BK4132","159992","00867","SG9999015945.SGD","IE00BYV24P56.USD","AD"],"gpt_icon":0},{"id":"2613794846","title":"申联生物最新公告：拟2.37亿元收购世之源控股权并开展创新药业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794846","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613794846?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:40","pubTimestamp":1771926009,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司拟使用2.37亿元自有资金及自筹资金，通过全资子公司上海本天成生物医药有限公司以股权转让及增资方式取得扬州世之源生物科技有限责任公司的控股权。交易完成后，本天成及其一致行动人将合计持有世之源51%的股权，世之源成为公司的控股孙公司，纳入上市公司合并报表范围。公司将全面开展创新药业务，形成“人用药品”与“动物保健”双主业协同发展的新格局。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","BK0239","688098","BK1161","BK1574"],"gpt_icon":0},{"id":"2613862796","title":"恒瑞医药(600276.SH)：1类创新药SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2613862796","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613862796?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:44","pubTimestamp":1771922674,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 恒瑞医药 发布公告，近日，公司子公司北京盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司1类创新药SHR-1918注射液的药品上市许可申请获受理，且已被纳入优先审评程序。SHR-1918注射液是公司自主研发的血管生成素样蛋白3单克隆抗体，通过抑制ANGPTL3的活性，从而降低血清中的甘油三酯和LDL-C水平。经查询EvaluatePharma数据库，该产品2025年全球销售额约为2.16亿美元。截至目前，SHR-1918注射液相关项目累计研发投入约24,220万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","LU2097828631.EUR","LU1580142542.USD","BK1574","LU1146622755.USD","LU2488822045.USD","LU2543165471.USD","BK0060","BK0196","LU1255011170.USD","BK0183","BK0012","LU2289578879.USD","BK0028","BK1161","LU2328871848.SGD","LU2097828805.USD","LU1064131003.USD","LU2148510915.USD","BK0239","LU2580892789.USD","LU1655091616.SGD","LU0359201612.USD","LU1820825898.SGD","LU2580892862.HKD","LU1064130708.USD","LU0405327148.USD","BK1191","LU1969619763.USD","LU1023057109.AUD","LU0359202008.SGD","LU2097828714.EUR","LU0359201885.HKD","600276","LU1997244956.HKD","LU0405327494.USD","159992","LU2495084118.USD","LU1997245177.USD","LU1781817850.SGD","LU2097828557.USD","LU2097828474.EUR","LU1997245094.SGD","BK0188","LU1328615791.USD","01276"],"gpt_icon":0},{"id":"2612781204","title":"创新药BD热潮今年有望持续：肿瘤、代谢等多个领域有潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2612781204","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612781204?lang=zh_cn&edition=full","pubTime":"2026-02-19 08:14","pubTimestamp":1771460083,"startTime":"0","endTime":"0","summary":"2025年中国创新药的BD（业务拓展）出海引爆全球医药行业，2026年这一趋势有望持续。根据国家药监局此前公布的数据，2025年，中国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，创历史新高。BD热潮在2026年仍在持续，2026年前两个月已经有多笔BD官宣。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602193651489010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602193651489010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2612551224","title":"创新药出海刷新纪录！开年BD总额超300亿美元 “中国研发效率”备受看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2612551224","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612551224?lang=zh_cn&edition=full","pubTime":"2026-02-17 18:28","pubTimestamp":1771324119,"startTime":"0","endTime":"0","summary":"2026年以重磅BD强势开年，年初License-out交易首付款总额已超2025年的39%；","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260217/20260217182931_99455.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260217/20260217182931_99455.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2611719421","title":"永泰生物-B完成发行新可换股债券及票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2611719421","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611719421?lang=zh_cn&edition=full","pubTime":"2026-02-16 08:07","pubTimestamp":1771200420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　永泰生物-B（06978）发布公告，认购协议项下所有先决条件已获达成或豁免（倘适用），且本金总额为人民币2.7亿元的新可换股债券及本金额为人民币3000万元的票据已根据其条款及条件发行予投资者。于本公告日期，认购事项的代价已专门用作全数及最终清偿将于2026年2月20日到期的2023年可换股债券的本金额。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-02-16/doc-inhmyeev7568459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2611163244","title":"永泰生物-B(06978)完成发行新可换股债券及票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2611163244","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611163244?lang=zh_cn&edition=full","pubTime":"2026-02-13 22:44","pubTimestamp":1770993859,"startTime":"0","endTime":"0","summary":"智通财经APP讯，永泰生物-B(06978)发布公告，认购协议项下所有先决条件已获达成或豁免(倘适用)，且本金总额为人民币2.7亿元的新可换股债券及本金额为人民币3000万元的票据已根据其条款及条件发行予投资者。于本公告日期，认购事项的代价已专门用作全数及最终清偿将于2026年2月20日到期的2023年可换股债券的本金额。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2611315112","title":"恒瑞医药：公司自主研发的1类创新药硫酸艾玛昔替尼片已在国内获批，用于成人重度斑秃患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2611315112","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611315112?lang=zh_cn&edition=full","pubTime":"2026-02-13 20:49","pubTimestamp":1770986945,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：想咨询恒瑞有没有可能研发真正的生发药剂呢？恒瑞医药（600276.SH）2月13日在投资者互动平台表示，公司坚持科技创新与国际化发展战略，促进公司业绩可持续增长，以更好的发展回馈股东。公司自主研发的1类创新药硫酸艾玛昔替尼片已在国内获批，用于成人重度斑秃患者。（记者 张明双）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213204955a4a0e1fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213204955a4a0e1fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU0359201612.USD","LU0359202008.SGD","BK1161","BK1191","LU1023057109.AUD","01276","LU2543165471.USD","BK1574","LU0359201885.HKD"],"gpt_icon":0},{"id":"2611158108","title":"成都创新药龙头企业百利天恒，再冲港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611158108","media":"红星资本局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611158108?lang=zh_cn&edition=full","pubTime":"2026-02-13 18:08","pubTimestamp":1770977306,"startTime":"0","endTime":"0","summary":"2月10日，成都创新药龙头百利天恒（688506.SH）公告，公司2026年第一次临时股东会通过《关于延长公司发行H股并上市相关决议有效期的议案》，这意味着公司将继续向港股上市发起冲击。此前在2025年11月12日，百利天恒发布公告称，公司决定全球发售将会延迟，且将不会根据招股章程进行。这意味着其原计划11月17日港股挂牌上市的日程被搁置。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602133650512764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","06978","BK4588","VXUS","BK1574","BK4585","688506","91194","BK1161","159992","BK0239","VT"],"gpt_icon":0},{"id":"2611990950","title":"今年已有30家医药企业拟赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2611990950","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611990950?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:17","pubTimestamp":1770913020,"startTime":"0","endTime":"0","summary":"据北京商报记者不完全统计，今年开年40余日，已有约30家医药企业递表港交所。　　药企扎堆赴港，“创新”成为关键词。上述30家企业中，13家为带有特殊标识“B”的未盈利的创新药、创新医疗器械企业。此外，还有信立泰、海特生物两股已于年内官宣正在筹划赴港上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-13/doc-inhmqrvv9450966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HEXmain","SINA","BK1161","06978","BK4588","LABU","BK4585","09939","BK1515","BK1574"],"gpt_icon":0},{"id":"2610925678","title":"北京：推动商保公司与医药企业开展协商定价，加速商保创新药目录落地实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925678","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610925678?lang=zh_cn&edition=full","pubTime":"2026-02-12 19:38","pubTimestamp":1770896280,"startTime":"0","endTime":"0","summary":"推动建立商业保险公司与创新医药企业沟通机制，促进创新药械产品等信息共享与需求对接，积极引导商业保险公司将价格合理的创新药械及基本医保目录外的肿瘤、细胞基因治疗、罕见病相关高值药械、高额诊疗项目等纳入保障范围，提高重大疾病保障能力。完善商保创新药遴选与准入机制，探索通过企业申报和专家评审相结合的方式，推动商业保险公司与医药企业开展协商定价，加速商保创新药目录落地实施。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-12/doc-inhmqfhc6783309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","06978"],"gpt_icon":0},{"id":"2610945012","title":"华商基金孙蔚：中国创新药产业全球地位显著提升 或推动产业链全面复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2610945012","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610945012?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:11","pubTimestamp":1770887460,"startTime":"0","endTime":"0","summary":"新春序幕将启，当此岁序交替之际，投资者该如何穿越市场短期波动、把握长期投资价值？华商健康生活灵活配置混合基金经理孙蔚表示，中国医药创新产业的全球地位显著提升，有望推动全产业链实现全面复苏；有色金属行业在多重利好共振下，高景气度有望延续；AI行业则进入算力与应用协同爆发、业绩兑现的关键阶段。她将重点跟踪上述领域，把握产业链变迁脉络，为投资者捕捉时代机遇。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-02-12/doc-inhmpyyf6852611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","06978"],"gpt_icon":0},{"id":"2610268279","title":"创新药退潮，博纳西亚赴港，一场“效率型外包”的暗战打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2610268279","media":"港股研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610268279?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:52","pubTimestamp":1770886343,"startTime":"0","endTime":"0","summary":"当中国创新药管线数量持续增长、药企数量快速增加，而真正具备大规模临床执行能力的企业却有限时，CRO的角色自然从“辅助服务商”转向“效率中枢”。博纳西亚，正是在这种结构变化中出现的样本。博纳西亚的策略也印证了这一点。这也是博纳西亚选择赴港上市的真正动因。但无论结果如何，博纳西亚的出现已经说明一个事实：中国CRO行业正在进入新的阶段。创新药退潮，并没有让医药产业降温，只是把价值重新分配给更能提高效率的人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212171215a49bc96a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212171215a49bc96a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1161","BK1574","06978","03759","BK1583","03347","BK1141","02359"],"gpt_icon":0},{"id":"2610914049","title":"创新药出海加速，带动CXO景气度回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2610914049","media":"云掌财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610914049?lang=zh_cn&edition=full","pubTime":"2026-02-12 15:14","pubTimestamp":1770880458,"startTime":"0","endTime":"0","summary":"2026年中国创新药延续凶猛的出海BD势头。华兴证券发布研报称，创新药投资、研发的日益活跃，对临床CRO、SMO等外包需求、订单加速恢复，为CXO行业景气度回升提供保障。截至发稿，药明康德、昭衍新药等板块相关个股均涨超2%。在基本面上，CXO景气度提升可以在龙头业绩上看到端倪。随着创新药研发火热，预计CXO行业将保持良好的景气度，值得密切关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212151423a49b4a19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212151423a49b4a19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0052750758.USD","LU0708995583.HKD","BK1574","LU2125910500.SGD","06978","LU2242644610.SGD","LU1046422090.SGD","BK1161","02359","BK1141","LU0320764599.SGD","LU2045819591.USD","BK1576","BK1583"],"gpt_icon":0},{"id":"2610914625","title":"千红制药：公司高度重视创新药研发及人才队伍建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2610914625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610914625?lang=zh_cn&edition=full","pubTime":"2026-02-12 15:06","pubTimestamp":1770879979,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药02月12日在投资者关系平台上答复投资者关心的问题。目前公司的人才招聘是不是太保守了？感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200018920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","002550","BK1161","BK0239","BK1574"],"gpt_icon":0},{"id":"2610957679","title":"国信证券：医药生物行业关注低估值和业绩修复的服务及消费板块 创新药出海合作持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2610957679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610957679?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:18","pubTimestamp":1770859099,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，医疗服务和消费相关等板块经历长期调整后估值处于历史低位。同时，国产创新药出海持续深化，中国创新药的研发效率与成本优势获国际认可。创新药出海合作持续深化近期，石药集团和信达生物分别与阿斯利康和礼来达成重磅合作协议。国产创新药的出海仍在继续，基于技术平台的多项目的合作协议表明了中国创新药的研发能力不断获得跨国药企的认可，中国创新药的效率优势、成本优势得到持续的体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","002736","BK1574","BK0188","000808.SH","06978","BK1161","BK0183","159992","BK0276","163118"],"gpt_icon":0},{"id":"2610099880","title":"【ETF动向】2月11日银华中证创新药产业ETF基金跌0.24%，份额减少9420万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610099880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610099880?lang=zh_cn&edition=full","pubTime":"2026-02-12 08:04","pubTimestamp":1770854663,"startTime":"0","endTime":"0","summary":"证券之星消息，2月11日，银华中证创新药产业ETF基金（159992）跌0.24%，成交额4亿元。当日份额减少了9420万份，最新份额为183.51亿份，近20个交易日份额增加19.06亿份。当日资金净流出9453.41万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为155.41亿元。银华中证创新药产业ETF基金跟踪标的为中证创新药产业指数，成立（2020-03-20）以来超额回报为-7.63%，近一个月超额回报为0.01%，管理人为银华基金公司，基金经理为马君 王帅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200005020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2610993166","title":"恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2610993166","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610993166?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:37","pubTimestamp":1770809832,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持差异化研发策略，以临床需求为导向，利用领先的技术平台打造差异化创新产品矩阵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113648077695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","LU0359201612.USD","LU1255011170.USD","LU0359201885.HKD","LU1328615791.USD","BK0012","BK0239","LU2289578879.USD","LU2097828557.USD","LU1820825898.SGD","LU2580892862.HKD","LU2488822045.USD","LU2580892789.USD","BK0196","LU2097828714.EUR","600276","LU1781817850.SGD","LU0405327494.USD","LU1997245177.USD","BK0188","LU1580142542.USD","LU1997244956.HKD","LU2097828631.EUR","LU2543165471.USD","LU1146622755.USD","LU1655091616.SGD","BK1161","BK0060","LU2097828474.EUR","LU0405327148.USD","LU0359202008.SGD","LU1064130708.USD","159992","LU2328871848.SGD","LU1064131003.USD","BK0183","LU1023057109.AUD","LU2097828805.USD","BK1191","BK1574","LU2148510915.USD","01276","LU1997245094.SGD","LU2495084118.USD","BK0028","LU1969619763.USD"],"gpt_icon":0},{"id":"2610060144","title":"华东医药：创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程","url":"https://stock-news.laohu8.com/highlight/detail?id=2610060144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610060144?lang=zh_cn&edition=full","pubTime":"2026-02-11 11:33","pubTimestamp":1770780797,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药02月10日在投资者关系平台上答复投资者关心的问题。为啥别人能做到一个接一个的大单华东医药回复：您好！创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程。公司始终秉持开放合作战略，在强化自主研发的同时，积极与全球同行一起探索创新药管线的BD机会。未来如达成明确合作协议，公司将严格按照信息披露规则履行披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100014208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","06978","BK0132","000963","BK0196","BK1574","BK0187","BK1161","BK0188","159992","BK0175","LU1969619763.USD","LU2328871848.SGD","BK0209"],"gpt_icon":0},{"id":"2610958464","title":"系统性红斑狼疮治疗迎利好，诺诚健华、阿斯利康等多药企创新药获新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2610958464","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610958464?lang=zh_cn&edition=full","pubTime":"2026-02-11 11:23","pubTimestamp":1770780180,"startTime":"0","endTime":"0","summary":"全球超340万系统性红斑狼疮（SLE）患者，中国约100万，药物需求迫切。国内药企持续发力，2月10日，杭州尚健生物自主研发的SG301 SC注射液获受理，为国内首个获批临床的皮下注射抗CD38人源化单克隆抗体，早期临床数据显示其安全性和有效性良好；2月9日，诺诚健华自主研发的VAV1分子胶降解剂ICP-538获批开展临床研究，其核心产品奥布替尼用于治疗SLE的三期临床试验也已获批开展。国际药企也在加速布局，阿斯利康旗下生物制剂Saphnelo在亚洲人群中的III期临床试验取得积极成果，在降低疾病活动度和减少口服糖皮质激素用量方面均有改善。此外，已有多款创新药在中国获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211113516a6ed165b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211113516a6ed165b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0236},{"period":"1month","weight":0.0612},{"period":"3month","weight":-0.1216},{"period":"6month","weight":-0.5113},{"period":"1year","weight":-0.2758},{"period":"ytd","weight":-0.1126}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0124},{"period":"3month","weight":0.0459},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0566}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.172633},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}